Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-060 in Relapsed/Refractory ALCL
NCT00298467Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of iratumumab in anaplastic large cell lymphoma (ALCL), sponsored by Bristol Myers Squibb. Planned start Feb 2006; status: withdrawn.
02
Drugs
iratumumab
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00298467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298467.